Skip to main
CDNA
CDNA logo

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc. is exhibiting strong performance with a notable 19% year-over-year growth in kidney surveillance volumes in Q2 2025, indicating increased demand for its testing services. The company has strategically expanded its sales force by approximately 50%, which is expected to enhance its market penetration and revenue growth over the coming months as the new representatives ramp up. Additionally, CareDx has set a targeted EBITDA margin of 20% for 2027, along with an ambition to boost its three-year incremental cash target by over $100 million, reflecting a commitment to improving financial performance and operational efficiency.

Bears say

CareDx Inc has faced significant risks stemming from multiple changes in management over the past three years, which may undermine operational stability and strategic direction. The company's growth strategy crucially relies on the successful commercialization of additional diagnostic solutions; however, there is skepticism surrounding this capability. Furthermore, while CareDx has expressed hopes for reimbursement increases for kidney testing, there is a noted lack of confidence in achieving these expansions, adding to the uncertainty about future revenue growth.

CareDx (CDNA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 6 analysts, CareDx (CDNA) has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.